One-Year Data Presented for Abbott Vascular's MitraClip TMVR System
March 18, 2017—Abbott Vascular announced 1-year outcomes from the United States study of real-world experience for the company's MitraClip transcatheter mitral valve repair (TMVR) system to treat patients with degenerative mitral regurgitation (DMR).
Paul Sorajja, MD, principal investigator of the study, presented the data during a featured clinical research session at ACC.17, the American College of Cardiology's 66th annual scientific session in Washington, DC.
According to Abbott, the study analyzed data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry involving approximately 3,000 DMR patients who were high risk for surgery. After TMVR with the MitraClip, patients had significant improvements.
The data showed that 92.8% of patients achieved postprocedural mitral regurgitation (MR) severity grade of ≤ 2 (acute procedural success defined as MR ≤2); 80% of MitraClip patients remained free from heart failure rehospitalization in the year after implantation; and 85.9% of patients were discharged to their homes after an average hospital stay of 2 days. The average age of patients was 82 years, noted Abbott Vascular.
In the company's press release, Dr. Sorajja commented, "The consistent 1-year results seen in this study validate that treatment with MitraClip can provide meaningful reduction in the severity of mitral regurgitation. The consistency of data over time in this large patient registry underscore the valuable impact MitraClip has on the overall health of very sick people living with this silent killer." Dr. Sorajja is Director of the Center of Valve and Structural Heart Disease at Minneapolis Heart Institute, and cardiologist at Abbott Northwestern Hospital in Minneapolis, Minnesota.